Approach to Myelopathy

Tracey A. Cho, MD, FAAN; Shamik Bhattacharyya, MD, MS Spinal Cord Disorders p. 386-406 April 2018, Vol.24, No.2 doi: 10.1212/CON.0000000000000583
REVIEW ARTICLES
BROWSE ARTICLES
Article as PDF
-- Select an option --

PURPOSE OF REVIEW Myelopathy is commonly encountered in clinical practice and is associated with a large number of causes. This article reviews the anatomy of the spinal cord and discusses how the clinical findings, time course, and radiographic patterns can help to identify the causes of myelopathy.

RECENT FINDINGS Imaging observations such as MRI “pancake” gadolinium enhancement pattern with spondylotic myelopathy and subpial enhancement with neurosarcoidosis have improved diagnostic specificity. On the other hand, common diseases such as degenerative spine disease are now recognized as presenting much more variably. Improved imaging and the identification of genetic markers enhance the specificity of diagnosis. The improved identification of biomarkers has shown that the same cause, such as compressive myelopathy, can present more variably than previously appreciated.

SUMMARY Spinal cord dysfunction, or myelopathy, remains a clinical diagnosis, and determining the cause requires integration of clinical, laboratory, and imaging parameters, none of which have great specificity individually. Most cases of myelopathy will require further neuroimaging, and some require CSF analysis for diagnosis. This article presents an approach to the diagnosis of myelopathy based on excluding compressive myelopathy initially and then differentiating between acute and subacute processes and chronic causes.

Address correspondence to Dr Tracey A. Cho, Massachusetts General Hospital, Neurology Department, 55 Fruit St, Boston, MA 02114, [email protected].

RELATIONSHIP DISCLOSURE: Dr Cho has received personal compensation as a case adjudicator of a safety study for Optum, Inc, on behalf of Merck & Co, Inc. Dr Bhattacharyya has received personal compensation for serving as a speaker for the American Academy of Neurology.

UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Cho and Bhattacharyya discuss the unlabeled/investigational use of corticosteroids in the management of neurosarcoidosis.

CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE

SUPPLEMENTAL DIGITAL CONTENT (SDC) AVAILABLE ONLINE

VIDEO CONTENT AVAILABLE ONLINE

© 2018 American Academy of Neurology.